These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30946491)

  • 21. Liposomes bearing fibrinogen could potentially interfere with platelet interaction and procoagulant activity.
    Hernández MR; Urbán P; Casals E; Estelrich J; Escolar G; Galán AM
    Int J Nanomedicine; 2012; 7():2339-47. PubMed ID: 22654514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversal of dabigatran by intraosseous or intravenous idarucizumab in a porcine polytrauma model.
    Akman N; Braunschweig T; Honickel M; Schütt K; Schöchl H; Stoppe C; Rossaint R; Grottke O
    Br J Anaesth; 2018 May; 120(5):978-987. PubMed ID: 29661415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of combined idarucizumab and prothrombin complex concentrate treatment for bleeding related to dabigatran in a lethal porcine model of double trauma.
    Honickel M; Braunschweig T; Rossaint R; Schöchl H; Grottke O
    Transfusion; 2019 Apr; 59(4):1376-1387. PubMed ID: 30586470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of experimental haemodilution on platelet function, thrombin generation and clot firmness: effects of different coagulation factor concentrates.
    Caballo C; Escolar G; Diaz-Ricart M; Lopez-Vílchez I; Lozano M; Cid J; Pino M; Beltrán J; Basora M; Pereira A; Galan AM
    Blood Transfus; 2013 Jul; 11(3):391-9. PubMed ID: 23058866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-Dose Dabigatran Is an Effective Anticoagulant for Simulated Cardiopulmonary Bypass Using Human Blood.
    Nadtochiy SM; Baldzizhar A; Stefanos T; Feng C; O'Leary KE; Jones-Smith KL; Angona RE; Eaton MP
    Anesth Analg; 2021 Feb; 132(2):566-574. PubMed ID: 32833714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
    Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
    Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P
    Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in vitro study.
    Dubut J; Goin V; Derray C; Huguenin Y; Fiore M
    J Thromb Haemost; 2024 Sep; 22(9):2589-2600. PubMed ID: 38880178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of patients post reversal with idarucizumab.
    Raco V; Ahuja T; Green D
    J Thromb Thrombolysis; 2018 Nov; 46(4):466-472. PubMed ID: 30120649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury.
    Sheikh-Taha M
    Am J Health Syst Pharm; 2019 Jan; 76(1):9-12. PubMed ID: 31381100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversing the anticoagulation effects of dabigatran.
    Dager WE; Banares L
    Hosp Pract (1995); 2017 Apr; 45(2):29-38. PubMed ID: 28335637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
    Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
    Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
    Miyares MA; Kuyumjian Y; Eaves S; Dollard E
    J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
    Syed YY
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incomplete dabigatran reversal with idarucizumab.
    Steele AP; Lee JA; Dager WE
    Clin Toxicol (Phila); 2018 Mar; 56(3):216-218. PubMed ID: 28704111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
    Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
    Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemostatic Therapy Using Tranexamic Acid and Coagulation Factor Concentrates in a Model of Traumatic Liver Injury.
    Zentai C; van der Meijden PE; Braunschweig T; Hueck N; Honickel M; Spronk HM; Rossaint R; Grottke O
    Anesth Analg; 2016 Jul; 123(1):38-48. PubMed ID: 27192476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.